{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:23:37Z","timestamp":1701735817819},"reference-count":0,"publisher":"Polskie Towarzystwo Biochemiczne (Polish Biochemical Society)","issue":"3","license":[{"start":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T00:00:00Z","timestamp":1693699200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Postepy Biochem"],"abstract":"<jats:p>Czerniak z\u0142o\u015bliwy to niebezpieczny rak sk\u00f3ry, odpowiadaj\u0105cy za wi\u0119kszo\u015b\u0107 zgon\u00f3w zwi\u0105zanych z nowotworami sk\u00f3ry. U wielu pacjent\u00f3w choruj\u0105cych na tego raka, kom\u00f3rki nowotworowe posiadaj\u0105 mutacj\u0119 V600E w genie BRAF. Mutacja ta powoduje konstytutywn\u0105 aktywacj\u0119 szlaku sygna\u0142owego MAPK\/ERK, przyczyniaj\u0105c si\u0119 znacz\u0105co do procesu kancerogenezy. W niniejszym artykule zosta\u0142 om\u00f3wiony proces projektowania lek\u00f3w na przyk\u0142adzie specyficznego inhibitora dla BRAF V600E, wemurafenibu. Na pocz\u0105tku zaprezentowane s\u0105 najcz\u0119\u015bciej stosowane metody projektowania lek\u00f3w. Druga cz\u0119\u015b\u0107 artyku\u0142u skupia si\u0119 na wemurafenibie. Przedstawiony jest proces pierwszej syntezy tego inhibitora BRAF V600E oraz jego analogu i przebieg trzech etap\u00f3w bada\u0144 klinicznych. Na rynku wemurafenib jest sprzedawany w postaci leku Zelboraf. Dalej znajduje si\u0119 opis innych popularnych lek\u00f3w na czerniaka z\u0142o\u015bliwego czyli dakarbazyny, ipilimumabu i dabrafenibu oraz kr\u00f3tka charakterystyka zalet terapii z r\u00f3wnoczesnym zastosowaniem dw\u00f3ch inhibitor\u00f3w. Na ko\u0144cu kr\u00f3tko om\u00f3wiona jest rola sztucznej inteligencji w przysz\u0142o\u015bci projektowania lek\u00f3w.<\/jats:p>","DOI":"10.18388\/pb.2021_498","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T11:08:33Z","timestamp":1701688113000},"page":"178-187","source":"Crossref","is-referenced-by-count":0,"title":["Od mutacji do leku"],"prefix":"10.18388","volume":"69","author":[{"given":"Jan","family":"Wnuk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Wilanowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7609","published-online":{"date-parts":[[2023,9,3]]},"container-title":["Post\u0119py Biochemii"],"original-title":[],"link":[{"URL":"https:\/\/postepybiochemii.ptbioch.edu.pl\/index.php\/PB\/article\/download\/498\/1267","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/postepybiochemii.ptbioch.edu.pl\/index.php\/PB\/article\/download\/498\/1277","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/postepybiochemii.ptbioch.edu.pl\/index.php\/PB\/article\/download\/498\/1268","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/postepybiochemii.ptbioch.edu.pl\/index.php\/PB\/article\/download\/498\/1267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T11:08:34Z","timestamp":1701688114000},"score":1,"resource":{"primary":{"URL":"https:\/\/postepybiochemii.ptbioch.edu.pl\/index.php\/PB\/article\/view\/498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,3]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9,25]]}},"URL":"https:\/\/doi.org\/10.18388\/pb.2021_498","relation":{},"ISSN":["0032-5422"],"issn-type":[{"value":"0032-5422","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,3]]}}}